Literature DB >> 25635055

Cellular inhibitor of apoptosis protein 1 (cIAP1) stability contributes to YM155 resistance in human gastric cancer cells.

Soo-A Jung1, Yong-Man Park1, Seung-Woo Hong1, Jai-Hee Moon1, Jae-Sik Shin1, Ha-Reum Lee2, Seung-Hee Ha1, Dae-Hee Lee1, Jeong Hee Kim1, Seung-Mi Kim1, Jeong Eun Kim1, Kyu-pyo Kim1, Yong Sang Hong1, Eun Kyung Choi3, Jung Shin Lee1, Dong-Hoon Jin4, TaeWon Kim5.   

Abstract

YM155, which blocks the expression of survivin, a member of the inhibitor of apoptosis (IAP) family, induces cell death in a variety of cancer types, including prostate, bladder, breast, leukemia, and non-small lung cancer. However, the mechanism underlying gastric cancer susceptibility and resistance to YM155 is yet to be specified. Here, we demonstrate that cIAP1 stability dictates resistance to YM155 in human gastric cancer cells. Treatment of human gastric cancer cells with YM155 differentially induced cell death dependent on the stability of cIAP1 as well as survivin. Transfection with cIAP1 expression plasmids decreased cell sensitivity to YM155, whereas knockdown of endogenous cIAP1 using RNA interference enhanced sensitivity to YM155. In addition, double knockdown of survivin and cIAP1 significantly induced cell death in the YM155-resistant cell line, MKN45. We also showed that YM155 induced autoubiquitination and proteasome-dependent degradation of cIAP1. Surprisingly, survivin affected the stability of cIAP1 through binding, contributing to cell sensitivity to YM155. Thus, our findings reveal that YM155 sensitizes human gastric cancer cells to apoptotic cell death by degrading cIAP1, and furthermore, cIAP1 in gastric cancer cells may act as a PD marker for YM155 treatment.
© 2015 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  Anticancer Drug; Apoptosis; Gastric Cancer; Survivin; Ubiquitylation (Ubiquitination); YM155, cIAP1

Mesh:

Substances:

Year:  2015        PMID: 25635055      PMCID: PMC4400372          DOI: 10.1074/jbc.M114.600874

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.486


  22 in total

1.  Ubiquitin protein ligase activity of IAPs and their degradation in proteasomes in response to apoptotic stimuli.

Authors:  Y Yang; S Fang; J P Jensen; A M Weissman; J D Ashwell
Journal:  Science       Date:  2000-05-05       Impact factor: 47.728

Review 2.  Targeted therapy in advanced colon cancer: the role of new therapies.

Authors:  J Tabernero; R Salazar; E Casado; E Martinelli; P Gómez; J Baselga
Journal:  Ann Oncol       Date:  2004       Impact factor: 32.976

3.  Suppression of survivin promoter activity by YM155 involves disruption of Sp1-DNA interaction in the survivin core promoter.

Authors:  Qiuying Cheng; Xiang Ling; Andrew Haller; Takahito Nakahara; Kentaro Yamanaka; Aya Kita; Hiroshi Koutoku; Masahiro Takeuchi; Michael G Brattain; Fengzhi Li
Journal:  Int J Biochem Mol Biol       Date:  2012-05-18

Review 4.  Targeted therapeutic strategies for the management of renal cell carcinoma.

Authors:  Eric A Singer; Gopal N Gupta; Ramaprasad Srinivasan
Journal:  Curr Opin Oncol       Date:  2012-05       Impact factor: 3.645

5.  Ribosomal S6 kinase 2 is a key regulator in tumor promoter induced cell transformation.

Authors:  Yong-Yeon Cho; Ke Yao; Hong-Gyum Kim; Bong Seok Kang; Duo Zheng; Ann M Bode; Zigang Dong
Journal:  Cancer Res       Date:  2007-09-01       Impact factor: 12.701

6.  Control of apoptosis and mitotic spindle checkpoint by survivin.

Authors:  F Li; G Ambrosini; E Y Chu; J Plescia; S Tognin; P C Marchisio; D C Altieri
Journal:  Nature       Date:  1998-12-10       Impact factor: 49.962

7.  YM155 reverses cisplatin resistance in head and neck cancer by decreasing cytoplasmic survivin levels.

Authors:  Bhavna Kumar; Arti Yadav; James C Lang; Michael J Cipolla; Alessandra C Schmitt; Nicole Arradaza; Theodoros N Teknos; Pawan Kumar
Journal:  Mol Cancer Ther       Date:  2012-06-21       Impact factor: 6.009

8.  Survivin-T34A: molecular mechanism and therapeutic potential.

Authors:  Jonathan R Aspe; Nathan R Wall
Journal:  Onco Targets Ther       Date:  2010-12-06       Impact factor: 4.147

9.  Synergistic antitumor activities of sepantronium bromide (YM155), a survivin suppressant, in combination with microtubule-targeting agents in triple-negative breast cancer cells.

Authors:  Naoki Kaneko; Kentaro Yamanaka; Aya Kita; Kenji Tabata; Takafumi Akabane; Masamichi Mori
Journal:  Biol Pharm Bull       Date:  2013       Impact factor: 2.264

10.  Sepantronium bromide (YM155) induces disruption of the ILF3/p54(nrb) complex, which is required for survivin expression.

Authors:  Tomohiro Yamauchi; Naoto Nakamura; Masashi Hiramoto; Masatoshi Yuri; Hiroyuki Yokota; Masanori Naitou; Masahiro Takeuchi; Kentaro Yamanaka; Aya Kita; Takahito Nakahara; Isao Kinoyama; Akira Matsuhisa; Naoki Kaneko; Hiroshi Koutoku; Masao Sasamata; Masato Kobori; Masao Katou; Shuichi Tawara; Shigeki Kawabata; Kiyoshi Furuichi
Journal:  Biochem Biophys Res Commun       Date:  2012-07-27       Impact factor: 3.322

View more
  8 in total

Review 1.  A comprehensive review of the roles of E2F1 in colon cancer.

Authors:  Zejun Fang; Min Lin; Chunxiao Li; Hong Liu; Chaoju Gong
Journal:  Am J Cancer Res       Date:  2020-03-01       Impact factor: 6.166

2.  Growth Hormone Mediates Its Protective Effect in Hepatic Apoptosis through Hnf6.

Authors:  Kewei Wang; Minhua Wang; Maureen Gannon; AiXuan Holterman
Journal:  PLoS One       Date:  2016-12-09       Impact factor: 3.240

3.  Bone morphogenetic protein and activin membrane-bound inhibitor overexpression inhibits gastric tumor cell invasion via the transforming growth factor-β/epithelial-mesenchymal transition signaling pathway.

Authors:  Chun-Ling Yuan; Rong Liang; Zhi-Hui Liu; Yong-Qiang Li; Xiao-Ling Luo; Jia-Zhou Ye; Yan Lin
Journal:  Exp Ther Med       Date:  2018-04-20       Impact factor: 2.447

4.  YM155-Adapted Cancer Cell Lines Reveal Drug-Induced Heterogeneity and Enable the Identification of Biomarker Candidates for the Acquired Resistance Setting.

Authors:  Martin Michaelis; Mark N Wass; Ian Reddin; Yvonne Voges; Florian Rothweiler; Stephanie Hehlgans; Jaroslav Cinatl; Marco Mernberger; Andrea Nist; Thorsten Stiewe; Franz Rödel; Jindrich Cinatl
Journal:  Cancers (Basel)       Date:  2020-04-26       Impact factor: 6.639

5.  Mixed lineage kinase-4 promotes gastric carcinoma tumorigenesis through suppression of the c-Jun N-terminal kinase signaling pathway.

Authors:  Yu Xi; Jianhua Niu; Dongmei Li; Jiagen He; Le Qin; Xinyu Peng
Journal:  Exp Ther Med       Date:  2018-08-20       Impact factor: 2.447

6.  cIAP1 promotes proliferation and migration and prevents apoptosis in gallbladder cancer in vitro.

Authors:  Wei Su; Xiaojie Jiang; Mingyuan Chen; Maotuan Huang; Nanhong Tang; Xiaoqian Wang; Xiujin Li; Feifei She; Yanlin Chen
Journal:  Biosci Rep       Date:  2019-04-12       Impact factor: 3.840

7.  Cancer genes disfavoring T cell immunity identified via integrated systems approach.

Authors:  Rigel J Kishton; Shashank J Patel; Amy E Decker; Suman K Vodnala; Maggie Cam; Tori N Yamamoto; Yogin Patel; Madhusudhanan Sukumar; Zhiya Yu; Michelle Ji; Amanda N Henning; Devikala Gurusamy; Douglas C Palmer; Roxana A Stefanescu; Andrew T Girvin; Winifred Lo; Anna Pasetto; Parisa Malekzadeh; Drew C Deniger; Kris C Wood; Neville E Sanjana; Nicholas P Restifo
Journal:  Cell Rep       Date:  2022-08-02       Impact factor: 9.995

8.  Application of novel targeting nanoparticles contrast agent combined with contrast-enhanced computed tomography during screening for early-phase gastric carcinoma.

Authors:  Kaimin Zhang; Xijian Du; Kaihu Yu; Kaiyu Zhang; Yicheng Zhou
Journal:  Exp Ther Med       Date:  2017-10-30       Impact factor: 2.447

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.